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ABSTRACT
Background: Symptom and medication scores are recommended to measure the primary outcome on aller-
gies. The Allergy Control Score was proved to be a valid and reliable instrument to assess allergy severity in
clinical trials and may be used in observational studies of respiratory allergic diseases in many countries. We
translated the Allergy Control Score and adapted it for use in Japan.
Methods: We translated the original English version into Japanese according to the Mapi approach to linguis-
tic validation: conceptual definition, forward translation by two native Japanese speakers, reconciliation, back-
translation by an independent translator, review in consultation with original developer, and pilot testing on 12
patients of an allergy clinic and 3 volunteers with seasonalnon-seasonal allergic rhinitis andor asthma.
Results: Two of the ten back-translated items needed slight modifications and some words were revised. In
the pilot test, the average time required to complete the questionnaire was 55 seconds for the section on symp-
toms and 25 seconds for the section on medication. All participants were able to self-complete the question-
naire.
Conclusions: By applying the Mapi approach to linguistic validation, we ensured a close match between the
Japanese and English versions of the Allergy Control Score. The Allergy Control Score Japanese version is ac-
cessible and acceptable to persons with respiratory allergic symptoms in Japan.
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INTRODUCTION
Symptom and medication scores are recommended
to measure the primary outcome of clinical trials on
respiratory allergies,1 and their use is proposed by in-
ternational regulatory agencies, such as the Euro-
pean Medicines Agency (EMEA).2 However, vali-
dated symptom and medication scores assessing res-
piratory allergy symptom are currently not available
in Japan. The Allergy Control Score (ACS) was devel-
oped and has been used successfully in multiple clini-
cal trials in Europe3-5; it was validated by assessing re-
producibility, discrimination capacity, and feasibility
in healthy controls and patients with respiratory aller-
gies.6 Convergent reliability analysis indicated a
highly significant correlation between ACS and global
allergy severity (P < 0.0001), quality of life (P
< 0.0001), and allergy-related medical consultations
(P < 0.0001). Scores were highly related to pollen
counts. ACS showed a good retest reliability (r = 0.81;
P < 0.0001) and discriminated well between patients
with allergy and healthy controls with a sensitivity of
97% and a specificity of 87%. Study participants evalu-
ated the feasibility as excellent. The ACS was proved
to be a valid and reliable instrument to assess allergy
severity in clinical trials and observational studies of
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respiratory allergic diseases.
The objective of the present study was to develop a
translated Japanese version of the ACS, with subse-
quent linguistic validation among Japanese persons
with respiratory allergies.
METHODS
MAPI STANDARD LINGUISTIC VALIDATION
PROCESS
The Mapi approach to cross-cultural adaptation was
referenced and used in this study.7 The Mapi Re-
search Institute is an international research organiza-
tion that engages in translating and validating health-
related QOL questionnaire for cross-cultural use.8
More than 350 instruments into over 110 languages
have been translated and validated internationally
there.8 We followed their ‘standard linguistic valida-
tion process’, which deals with questionnaire devel-
oped in English and needed in another language
andor culture. The Mapi Institute itself was not in-
volved in this study.
‘The standard linguistic validation process’ of the
Mapi Research Institute is composed of the following
stages:
- Conceptual definition: the developer of the ACS
and the researcher managing the linguistic valida-
tion process (the consultant) reviewed all items of
the questionnaire to clarify the concepts involved;
- Forward translation: the original instrument was
translated into Japanese by two translators, a
medical professional and a lay person, both native
Japanese speakers proficient in English. The con-
sultant re-conciliated the two translations and es-
tablished a consensus version;
- Backward translation: the consensus version was
back-translated into English by an independent
translator who was a native speaker of English
and had never seen the original version of ACS.
The consultant compared the back translation
and the original version and examined any dis-
crepancies between them. These were reviewed
by the developer of ACS to produce the pilot ver-
sion;
- Pilot testing: the Mapi approach pilot testing com-
prises 2 stages that take place in parallel: cogni-
tive debriefing, where the pilot version is tested
with a small sample from the target population (5-
10 subjects) to assess its relevance, clarity and in-
telligibility; and a clinician’s review, where an ex-
pert clinician reviews and offers feedback on the
pilot version.
- Proofreading: two rounds of proofreading ensured
the instrument was free of typing, spelling and
grammatical errors. This was done, as recom-
mended, by the consultant and one translator.
PILOT TESTING PARTICIPANTS AND PROCE-
DURE
The study protocol was approved by the Kyoto Uni-
versity Ethics Committee Review Board. The subjects
gave a written informed consent and patient anonym-
ity were preserved using documents and methods ap-
proved by the ethical review committee.
We recruited subjects with seasonalnon-seasonal
allergic rhinitis, allergic conjunctivitis, andor asthma
in Kyoto at a clinic and elementary school. Eligibility
criteria included a) suffering from seasonalnon-
seasonal allergic rhinitis andor asthma, and b) not
being a medical professional. A letter that included in-
formation on the project was given to each participant
by their physician (at a clinic), or by the investigator
(at an elementary school). Once written consent was
given, each participant filled out the following:
- Background information: age, sex, and allergic
disease history.
- Pilot version of ACS symptom and medication
parts. ACS symptom part consisted of 10 items
that covered 3 domains: nasal, eyes, and bron-
chial symptom. Scores range from 0 to 3 : 0 = ab-
sent (no signsymptom evident); 1 = mild (sign
symptom clearly present, but minimal awareness;
easily tolerated); 2 = moderate (definite aware-
ness of signsymptom that is bothersome, but tol-
erable); 3 = severe (signsymptom that is hard to
tolerate; causes interference with activities of
daily living andor sleeping). ACS medication
part consisted of 2 items; brand name of medica-
tion, and dosage on the day.
- Eleven questions on accessibility (e.g., ‘Did you
find any of the items difficult to understand?’), the
content validity and the acceptability of the ques-
tionnaire (e.g., ‘Do you think you would score
high on this questionnaire if you have severe al-
lergic symptom?’ ‘How difficult was it to respond
to the questionnaire?’ ‘Do you have any sugges-
tions on the questionnaire?).
DATA ANALYSIS
Descriptive analyses were used to assess the quality
of the translations. Time to complete and the percent-
age of missing data were calculated to assess how ac-
cessible and acceptable the questionnaire was to par-
ticipants. We also assessed the accessibilityaccept-
abilityvalidity of the questionnaire using a feasibility
questionnaire given to participants post-pilot. Partici-
pants’ reactions to the ACS questionnaire items were
observed to assess whether they misread any of
them, asked for clarification, or needed prompting to
answer them. The calculation of the J-ACS was done
as described in the original publication of the ACS.6
RESULTS
CONCEPTUAL DEFINITION
The consultant reviewed all instructions, items and
Allergy Control Score Japanese Version
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Table　1　Answers to feasibility questions
Feasibility Questions n 0 1 2 3
Do you have any items difficult to understand? (0 = no, 1 = yes) 15 15 0 0 0
Do you have any items difficult to answer? (0 = no, 1 = yes) 15 12 3
Do you think the items are easy to answer overall? (0 = yes, 1 = no) 15 15 0
How strenuous was it to respond to the questionnaire? (0 = not at all, 4 = very much) 15 13 2 0 0
How unpleasant was it to answer to the questions? (0 = not at all, 4 = very much) 15 15 0 0 0
Do you think you will have higher score at the questionnaire on the day you have severe allergic symptom? 
(0 = yes, 1 = no)
15 14 1
I appraised the content of the questionnaire altogether: (0 = very easy, 4 = very difficult) 15 15 0 0 0
How much did you have to think to answer the single questions? (0 = very little, 1 = little, 2 = some, 3 = much) 15 4 10 1 0
How comprehensible is the instruction on fi lling out questionnaire? (0 = very easy, 4 = very difficult) 15 13 2 0 0
How comprehensible is the instruction on the application of medication? (0 = very easy, 4 = very difficult) 15 9 6 0 0
Do you have any suggestions to the questionnaire? (0 = no, 1 = yes) 15 15 0
response choices of the ACS with the developer of
the instrument to ensure conceptual clarity.
TRANSLATIONS
The original ACS was translated into Japanese by two
native Japanese-speakers. The consensus version of
these two translations was then back-translated into
English. The back-translated version was compared
with the original ACS. The items used in the ques-
tionnaire were easily translated, and our results were
promising: Eight of the 10 back-translated items were
identical to the consensus version and another 2
slightly differed (‘watering’ to ‘tears’ and ‘itching’ to
‘ticklishness’). Accordingly, in consensus with origi-
nal developer, we re-transferred the two, which were
then back-translated essentially identical to the origi-
nal version but with slightly different in wording;
‘teary eyes’ and ‘itchiness (feeling itch)’. Six of the 7
direction sentences were essentially identical in
meaning but slightly different in wording. One direc-
tion sentence was slightly modified, but the differ-
ence was due to the back-translator’s error.
PILOT TEST
Clinician’s Review
The clinician reviewed the translated ACS and con-
firmed that the translated version of ACS was appro-
priate for Japanese patients with respiratory allergies.
However, the clinician proposed giving more exam-
ples in instruction to make the questionnaire more
user-friendly. In fact, the pilot testing revealed that
the instructions regarding items related to medica-
tions were not very easily comprehensible (Table 1).
In consensus with the original developer, we added
more examples to the instructions (Supplementary
Fig. 1).
Cognitive Debriefing
We administered the first version of J-ACS that in-
cluded translated items with no diary-styled items to
9 subjects. We then administered the second version
of J-ACS that included the diary style to 6 subjects.
Participants’ characteristics―Fifteen subjects with
seasonalnon-seasonal allergic rhinitis, andor
asthma were recruited from an allergy clinic and
from parents at an elementary school in Kyoto. Par-
ticipants comprised 2 men and 13 women, with an
age range of 16-60 years (mean 41 years, median 40
years). All participants had allergic rhinitis, eight
(53%) of which were seasonal, three (20%) with aller-
gic conjunctivitis, and two (13%) with asthma. All sub-
jects completed the questionnaire only once, ob-
served by the investigator at the clinic or at the
school. The one-day part of the diary-styled question-
naire was completed within 3 minutes (range: 40-123
seconds, mean 80 seconds; 55 seconds for symptom
part and 25 seconds for medication part).
Accessibility and acceptability of the ACS―All sub-
jects were able to self-complete the questionnaire.
They all found the questionnaire easy to answer over-
all and all replied that no items were difficult to un-
derstand. Two participants commented that the ques-
tionnaire was “slightly strenuous” while the other 13
participants chose “not strenuous at all”. Three par-
ticipants chose that they felt one item was difficult to
answer; one felt it was slightly difficult in judging if a
symptom was tolerable; another pointed out that he
could not judge if he should take into account his
cold symptom (sneeze). Because the second version
of ACS included a field to comment in that allowed
the users to describe their irrelevant symptoms (i.e.,
cold), we believe the second version of the J-ACS re-
solves all of the above concerns.
In addition to the above, one participant did not re-
member her medication name used on that day, but
commented that she would have noted the medica-
tion if she knew that she was going to be asked.
Again another participant did not specify her medica-
tion but commented that she could fill in the part
once she returned home. The problem of forgetting
the name of one’s medication could be resolved if the
participant was made aware of the need to know this
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Fig.　1　Distribution of J-ACS scores.
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information prior to filling out the questionnaire.
Content validity―No items needed specific clarifi-
cation. All but one subject commented that it was
easy to describe changes in severity of their allergic
symptom if the questionnaire once administered
daily. One patient with severe seasonal allergic rhini-
tis commented that she suffered intolerable allergic
symptoms daily during the spring, and some of her
symptom scores were fixed at 3 during the season,
suggesting a ceiling effect. However, once she was
explained that ACS uses the total score of all symp-
toms and medications used on the day, she agreed
that her score accurately reflected her symptom se-
verity on the day. Her clinician commented that she
suffered from severe seasonal allergic rhinitis, and
that her case was an outlier. In fact, the scores of the
questionnaire were well distributed across response
categories, and this patient had the highest score of
all the participants (Fig. 1).
DISCUSSION
This study linguistically validated the Allergy Control
Score for use with Japanese people with respiratory
allergic symptoms. The Mapi Institute guidelines was
referenced and used. Two native Japanese-speakers,
a medical professional and a layperson, translated the
instrument into Japanese. An independent translator
back-translated the consensus version of these two
translations into English to check equivalence with
the original ACS. We tested the pilot version of the
Japanese ACS on 15 subjects with respiratory allergic
symptom to evaluate its accessibility, acceptability
and content validity. Fifteen subjects recruited to the
study, all agreed to take part and all were eligible,
making the overall response rate (100%). The accessi-
bility of the J-ACS to subjects with respiratory allergic
symptoms is supported by the fact that all respon-
dents were able to complete the questionnaire within
3 minutes. The responses were well distributed
across response categories (Fig. 1), suggesting the
questionnaire items would discriminate well between
respondents. Although an extremely severe patient
pointed out a ceiling effect in the symptom score, she
later recognized that her medication score would be
added to the total score and that the J-ACS can dis-
criminate everyday changes in symptoms among se-
vere patients. Initial support for content validity for
this questionnaire was supported by the fact that no
one requested to add information to the question-
naire.
A limitation of this pilot study is its small sample of
participants. Although we followed the sample size
suggested by the Mapi guidelines (n = 5-10), we did
not carry out quality controls of data that require
large samples sizes, such as estimating Cronbach’s
alpha. Further validation is needed for use in clinical
research aimed to evaluate symptoms of allergic dis-
eases in Japan.
In Japan, nearly 40% of the population is reported to
have allergic rhinitis.9 Some patients do not regularly
consult a physician even though aware of their aller-
gic symptoms. We included such patients in cognitive
debriefing, and we did not observe any specific prob-
lems in answering the questionnaire. We believe our
results can be generalized not only to patients at clin-
ics but also to those with respiratory allergic symp-
toms who do not regularly consult a physician.
Using the Mapi approach to linguistic validation,
this study ensured a close match between the origi-
nal and Japanese ACS. The Japanese ACS is accessi-
ble and acceptable to persons with respiratory aller-
gic symptom in Japan.
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